"kaken pharm" - Google News

Number of shareholders of Kaken Pharmaceutical Co., Ltd. – OTC:KKPCF - TradingView

Fri, 12 Jun 2026 02:58:41 GMT

Number of shareholders of Kaken Pharmaceutical Co., Ltd. – OTC:KKPCF TradingView

Assessing Kaken Pharmaceutical’s (TSE:4521) Valuation After Recent Muted Share Price Momentum - Yahoo Finance

Fri, 27 Mar 2026 07:00:00 GMT

Assessing Kaken Pharmaceutical’s (TSE:4521) Valuation After Recent Muted Share Price Momentum Yahoo Finance

Why Kaken Pharmaceutical's (TSE:4521) Shaky Earnings Are Just The Beginning Of Its Problems - simplywall.st

Wed, 20 May 2026 07:00:00 GMT

Why Kaken Pharmaceutical's (TSE:4521) Shaky Earnings Are Just The Beginning Of Its Problems simplywall.st

Kaken Pharmaceutical Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:KKPCF) 2026-05-16 - Seeking Alpha

Sat, 16 May 2026 07:00:00 GMT

Kaken Pharmaceutical Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:KKPCF) 2026-05-16 Seeking Alpha

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire

Wed, 06 Aug 2025 07:00:00 GMT

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan Business Wire

Astria Therapeutics licenses navenibart rights to Kaken for HAE - Pharmaceutical Technology

Thu, 07 Aug 2025 07:00:00 GMT

Astria Therapeutics licenses navenibart rights to Kaken for HAE Pharmaceutical Technology

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria's navenibart in Japan - Fierce Biotech

Wed, 06 Aug 2025 07:00:00 GMT

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria's navenibart in Japan Fierce Biotech

Kaken Pharmaceutical stock (JP3292200007): focus on niche dermatology and Japanese market presence - AD HOC NEWS

Tue, 09 Jun 2026 12:50:10 GMT

Kaken Pharmaceutical stock (JP3292200007): focus on niche dermatology and Japanese market presence AD HOC NEWS

Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - PR Newswire

Wed, 26 Mar 2025 07:00:00 GMT

Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals PR Newswire

Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases - Pharmaceutical Executive

Fri, 03 Jan 2025 08:00:00 GMT

Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases Pharmaceutical Executive

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan - The Dermatology Digest

Thu, 27 Mar 2025 17:36:33 GMT

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan The Dermatology Digest

Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio - Wilson Sonsini

Fri, 20 Dec 2024 08:00:00 GMT

Wilson Sonsini Advises Aadi Bioscience on $100 Million Sale of FYARRO®, $100 Million PIPE Financing and License Agreement for ADC Portfolio Wilson Sonsini

Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire

Tue, 25 Mar 2025 07:00:00 GMT

Alumis and Kaken Pharmaceutical Announce Collaboration and GlobeNewswire

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal - PMLiVE

Mon, 06 Jan 2025 08:00:00 GMT

J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal PMLiVE

Japan's Kaken Pharma enters into license agreement for STAT6 inhibitor with Johnson & Johnson for $1.2 B - BioSpectrum Asia

Tue, 07 Jan 2025 08:00:00 GMT

Japan's Kaken Pharma enters into license agreement for STAT6 inhibitor with Johnson & Johnson for $1.2 B BioSpectrum Asia

Botanix announces regulatory approval of ECCLOCK in South Korea - BiotechDispatch

Mon, 08 Sep 2025 07:00:00 GMT

Botanix announces regulatory approval of ECCLOCK in South Korea BiotechDispatch

Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan - Fierce Biotech

Tue, 25 Mar 2025 07:00:00 GMT

Kaken agrees to $180M deal to develop Alumis' lead TYK2 inhibitor in Japan Fierce Biotech

KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology

Tue, 08 Apr 2025 07:00:00 GMT

KalVista licences HAE therapy commercialisation rights to Kaken Pharmaceutical Technology

Numab Therapeutics and Kaken Pharmaceutical Enter - GlobeNewswire

Fri, 15 Nov 2024 08:00:00 GMT

Numab Therapeutics and Kaken Pharmaceutical Enter GlobeNewswire

KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal - Fierce Biotech

Tue, 08 Apr 2025 07:00:00 GMT

KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal Fierce Biotech

Kaken Pharmaceutical divulges new STAT6 inhibitors - BioWorld News

Tue, 23 Apr 2024 07:00:00 GMT

Kaken Pharmaceutical divulges new STAT6 inhibitors BioWorld News

KalVista licensing deal with Kaken - The Pharma Letter

Wed, 09 Apr 2025 07:00:00 GMT

KalVista licensing deal with Kaken The Pharma Letter

Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset - Fierce Biotech

Fri, 15 Nov 2024 08:00:00 GMT

Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset Fierce Biotech

CymaBay Therapeutics Announces Collaboration with Kaken - GlobeNewswire

Sun, 08 Jan 2023 08:00:00 GMT

CymaBay Therapeutics Announces Collaboration with Kaken GlobeNewswire

Astria Licenses HAE Drug Navenibart to Japan’s Kaken in $32M+ Deal - BioPharma APAC

Fri, 08 Aug 2025 07:00:00 GMT

Astria Licenses HAE Drug Navenibart to Japan’s Kaken in $32M+ Deal BioPharma APAC

Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz

Wed, 26 Mar 2025 07:00:00 GMT

Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals citybiz

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Tue, 23 Dec 2025 08:00:00 GMT

KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema BioSpace

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld News

Fri, 27 Dec 2024 08:00:00 GMT

STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space BioWorld News

Rx Rundown: Metagenomi, Chiesi, Thermo Fisher Scientific and more - Medical Marketing and Media

Fri, 14 Nov 2025 08:00:00 GMT

Rx Rundown: Metagenomi, Chiesi, Thermo Fisher Scientific and more Medical Marketing and Media

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update - Business Wire

Wed, 25 Mar 2026 07:00:00 GMT

KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update Business Wire

Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis - PR Newswire

Tue, 27 Feb 2018 08:00:00 GMT

Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis PR Newswire

Kaken inks license agreement for STAT6 Inhibitor - The Pharma Letter

Fri, 27 Dec 2024 08:00:00 GMT

Kaken inks license agreement for STAT6 Inhibitor The Pharma Letter

Kaken licenses STAT6 program to J&J - BioWorld News

Fri, 27 Dec 2024 08:00:00 GMT

Kaken licenses STAT6 program to J&J BioWorld News

Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com

Wed, 26 Mar 2025 07:00:00 GMT

Whitehawk Therapeutics sells subsidiary for $102.4 million Investing.com

Almirall Insists Costly Ebglyss Launch Is Progressing Well - Citeline News & Insights

Mon, 11 Nov 2024 08:00:00 GMT

Almirall Insists Costly Ebglyss Launch Is Progressing Well Citeline News & Insights

Whitehawk Therapeutics - The Pharma Letter

Wed, 02 Apr 2025 08:48:30 GMT

Whitehawk Therapeutics The Pharma Letter

Alumis up 95% on envudeucitinib results in psoriasis - The Pharma Letter

Wed, 07 Jan 2026 08:00:00 GMT

Alumis up 95% on envudeucitinib results in psoriasis The Pharma Letter

Aadi Bioscience takes flight with new moniker: Whitehawk Therapeutics - Fierce Pharma

Tue, 18 Mar 2025 07:00:00 GMT

Aadi Bioscience takes flight with new moniker: Whitehawk Therapeutics Fierce Pharma

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target - MedCity News

Sun, 12 Jan 2025 08:00:00 GMT

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target MedCity News

In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings - Mintz

Thu, 12 Nov 2020 08:00:00 GMT

In Hatch-Waxman litigation, Federal Circuit restricts venue under the TC Heartland to districts relating to ANDA filings Mintz

JnJ enters licensing agreement for global development, manufacturing, commercialization of STAT6 program... - Medical Dialogues

Fri, 27 Dec 2024 08:00:00 GMT

JnJ enters licensing agreement for global development, manufacturing, commercialization of STAT6 program... Medical Dialogues

Numab, Kaken Establish Deal for Multispecific Antibody for Inflammatory Disease - Genetic Engineering and Biotechnology News

Tue, 13 Jun 2017 07:00:00 GMT

Numab, Kaken Establish Deal for Multispecific Antibody for Inflammatory Disease Genetic Engineering and Biotechnology News

4521 Stock Price and Chart — TSE:4521 - TradingView

Sun, 03 Sep 2017 22:40:39 GMT

4521 Stock Price and Chart — TSE:4521 TradingView

Dong-A ST releases Jublia, anti-toenail fungus agent - The Korea Post

Wed, 07 Jun 2017 07:00:00 GMT

Dong-A ST releases Jublia, anti-toenail fungus agent The Korea Post